Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial

Publication | Open Access

DOI Full Paper Access

301

Citations

References

2014

Year

Ajay Vora, Nick Goulden, Chris Mitchell, Jeremy Hancock, Rachael Hough, Clare Rowntree, Anthony V. Moorman, Rachel Wade

The Lancet Oncology

Hematological MalignancyPost-remission TherapyYoung PeopleOncologyPediatric EpidemiologyPediatric HematologyMixed-phenotype Acute LeukemiaClinical EpidemiologyClinical TrialsHematologyPediatricsOutcomes ResearchPublic HealthUkall 2003MedicineAdult T-cell Leukemia-lymphoma